Literature DB >> 27335276

Time-dependent changes in mortality and transformation risk in MDS.

Michael Pfeilstöcker1, Heinz Tuechler2, Guillermo Sanz3, Julie Schanz4, Guillermo Garcia-Manero5, Francesc Solé6, John M Bennett7, David Bowen8, Pierre Fenaux9, Francois Dreyfus10, Hagop Kantarjian5, Andrea Kuendgen11, Luca Malcovati12, Mario Cazzola12, Jaroslav Cermak13, Christa Fonatsch14, Michelle M Le Beau15, Marilyn L Slovak16, Alessandro Levis17, Michael Luebbert18, Jaroslaw Maciejewski19, Sigrid Machherndl-Spandl20, Silvia M M Magalhaes21, Yasushi Miyazaki22, Mikkael A Sekeres19, Wolfgang R Sperr23, Reinhard Stauder24, Sudhir Tauro25, Peter Valent26, Teresa Vallespi27, Arjan A van de Loosdrecht28, Ulrich Germing11, Detlef Haase4, Peter L Greenberg29.   

Abstract

In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2016        PMID: 27335276      PMCID: PMC5161006          DOI: 10.1182/blood-2016-02-700054

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Authors:  M G Della Porta; H Tuechler; L Malcovati; J Schanz; G Sanz; G Garcia-Manero; F Solé; J M Bennett; D Bowen; P Fenaux; F Dreyfus; H Kantarjian; A Kuendgen; A Levis; J Cermak; C Fonatsch; M M Le Beau; M L Slovak; O Krieger; M Luebbert; J Maciejewski; S M M Magalhaes; Y Miyazaki; M Pfeilstöcker; M A Sekeres; W R Sperr; R Stauder; S Tauro; P Valent; T Vallespi; A A van de Loosdrecht; U Germing; D Haase; P L Greenberg; M Cazzola
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

3.  Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.

Authors:  Daniel F Pease; Julie A Ross; Jenny N Poynter; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick
Journal:  Cancer Epidemiol       Date:  2015-02-18       Impact factor: 2.984

4.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Authors:  Luca Malcovati; Matteo G Della Porta; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Kathrin Nachtkamp; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

5.  Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes.

Authors:  Michael Pfeilstöcker; Heinz Tüchler; Anabel Schönmetzler; Thomas Nösslinger; Elisabeth Pittermann
Journal:  Leuk Res       Date:  2011-10-02       Impact factor: 3.156

6.  Myelodysplastic syndromes, version 2.2015.

Authors:  Peter L Greenberg; Richard M Stone; Rafael Bejar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Virginia Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Bart Scott; Paul J Shami; Brady L Stein; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

7.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

Authors:  Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre Issa; Emil J Freireich; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

8.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Authors:  Julie Schanz; Heinz Tüchler; Francesc Solé; Mar Mallo; Elisa Luño; José Cervera; Isabel Granada; Barbara Hildebrandt; Marilyn L Slovak; Kazuma Ohyashiki; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

9.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more
  42 in total

1.  Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

Authors:  Stephanie Guidez; Julien Labreuche; Elodie Drumez; Loic Ysebaert; Jana Bakala; Caroline Delette; Bénédicte Hivert; Caroline Protin; Hervé Declercq; Mélanie Verlay; Jean Pierre Marolleau; Alain Duhamel; Pierre Morel
Journal:  Blood Adv       Date:  2018-11-27

2.  [Myelodysplastic syndromes].

Authors:  Aristoteles Giagounidis
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

Review 3.  Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2020-05-18

Review 4.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

Authors:  Theo de Witte; David Bowen; Marie Robin; Luca Malcovati; Dietger Niederwieser; Ibrahim Yakoub-Agha; Ghulam J Mufti; Pierre Fenaux; Guillermo Sanz; Rodrigo Martino; Emilio Paolo Alessandrino; Francesco Onida; Argiris Symeonidis; Jakob Passweg; Guido Kobbe; Arnold Ganser; Uwe Platzbecker; Jürgen Finke; Michel van Gelder; Arjan A van de Loosdrecht; Per Ljungman; Reinhard Stauder; Liisa Volin; H Joachim Deeg; Corey Cutler; Wael Saber; Richard Champlin; Sergio Giralt; Claudio Anasetti; Nicolaus Kröger
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

5.  Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association?

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Haematologica       Date:  2018-05       Impact factor: 9.941

6.  Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Authors:  Andrew M Brunner; Traci M Blonquist; Gabriela S Hobbs; Philip C Amrein; Donna S Neuberg; David P Steensma; Gregory A Abel; Amir T Fathi
Journal:  Blood Adv       Date:  2017-10-18

Review 7.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  In MDS, is higher risk higher reward?

Authors:  Guillermo F Sanz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 9.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

10.  Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.